Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Aug 12;11(3):e005754.
doi: 10.1136/rmdopen-2025-005754.

Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease

Collaborators, Affiliations
Meta-Analysis

Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease

Carlos Rosa-Baez et al. RMD Open. .

Abstract

Objective: The common gain-of-function variant rs35705950, located in the promoter of MUC5B gene, has been strongly associated with interstitial lung diseases (ILDs) of different aetiology, such as idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-associated ILD (RA-ILD). In this study, we aimed to investigate the association of this variant and its nearby single nucleotide polymorphisms (SNPs) in the largest cohort of systemic sclerosis-associated ILD (SSc-ILD) to date.

Methods: Samples were collected from blood/saliva, followed by DNA extraction and genotyping using SNP arrays. Data for rs35705950 and additional 903 variants within 100 Kb were obtained using genomic imputation. Subsequently, we tested their association in a meta-analysis to increase the consistency of the results, including 10 European ancestry cohorts comprising 2363 patients with SSc-ILD, 3526 SSc patients without ILD and 15 076 controls.

Results: Meta-analysis showed no significant association between rs35705950 and SSc-ILD, either comparing patients with SSc with and without ILD (p value: 0.588, OR: 1.05, 95% CI: 0.87 to 1.27) nor patients with SSc-ILD with controls (p value: 0.061, OR: 1.16, 95% CI: 0.99 to 1.36). Moreover, none of the additional 903 variants tested in the genomic region reached statistical significance.

Conclusion: Despite analysing the largest and most statistically powered SSc-ILD cohort to date, we found no evidence of association between the MUC5B promoter variant rs35705950 and its surrounding SNPs with SSc-ILD. These results suggest that the pathogenic mechanisms underlying SSc-ILD may only partially overlap with those of other similar ILDs, such as IPF or RA-ILD. This highlights the need for further studies regarding their genetic architecture.

Keywords: Lung Diseases, Interstitial; Polymorphism, Genetic; Scleroderma, Systemic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SMP has received honoraria from Janssen, Boehringer Ingelheim, MSD. MN has received honoraria or consultancies from Janssen, AstraZeneca, GlaxoSmithKlein, Boehringer Ingelheim and Bristol Myers Squibb. The Australian Scleroderma Cohort Study (ASCS) is supported by Janssen, Boehringer Ingelheim, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia (muscle, bone and joint health), Australian Rheumatology Association and St Vincent’s Hospital Melbourne IT Department and Research Endowment Fund (REF).

Figures

Figure 1
Figure 1. Locus zooms of the region surrounding the MUC5B rs35705950 variant. A) Locus zoom of the region surrounding rs35705950 for the comparison of SSc-ILD versus patients with SSc without ILD. Variant rs35705950 is represented as a diamond, and other SNPs as dots. The colour of the dots indicates linkage disequilibrium with rs35705950. Dashed line corresponds to 5.53×10−5 significance threshold. (B) Locus zoom of the region surrounding rs35705950 for the comparison of SSc-ILD versus controls. Variant rs35705950 is represented as a diamond, and other SNPs as dots. The colour of the dots indicates linkage disequilibrium with rs35705950. The dashed line corresponds to 5.53×10−5 significance threshold. LD, linkage disequilibrium; SNP, single nucleotide polymorphism; SSc-ILD, systemic sclerosis-associated interstitial lung disease.

Similar articles

References

    1. Liakouli V, Ciancio A, Del Galdo F, et al. Systemic sclerosis interstitial lung disease: unmet needs and potential solutions. Nat Rev Rheumatol. 2024;20:21–32. doi: 10.1038/s41584-023-01044-x. - DOI - PubMed
    1. Spagnolo P, Distler O, Ryerson CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs) Ann Rheum Dis. 2021;80:143–50. doi: 10.1136/annrheumdis-2020-217230. - DOI - PMC - PubMed
    1. Bernstein EJ, Boin F, Elicker B, et al. FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Sunnyvale) doi: 10.1093/rheumatology/keae573. n.d. - DOI - PubMed
    1. Juge P-A, Borie R, Kannengiesser C, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J. 2017;49:1602314. doi: 10.1183/13993003.02314-2016. - DOI - PubMed
    1. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503–12. doi: 10.1056/NEJMoa1013660. - DOI - PMC - PubMed

Publication types

LinkOut - more resources